Galien week of innovation

Scott is currently Head of Business Development and Licensing, USA at Boehringer Ingelheim, based out of both Ridgefield, CT and Cambridge, MA.  He received his BS in Cellular Biology from the University of Connecticut in 1999 and began his research career with Pfizer in Groton, CT.  He later earned a PhD in Molecular Biology from the University of North Carolina, and did his postdoc the lab of Nobel Laureate Robert Lefkowitz at Duke University, studying G protein coupled receptor signaling.  In late 2007, Scott co-founded a start-up company called Trevena Inc ($TRVN on Nasdaq), helping discover and develop the pain therapy Olinvyk®.  After his startup adventure, Scott left Trevena to join BI, initially working in the research group on discovery programs that eventually became the FDA-approved drugs Skyrizi® and Spevigo®. Scott later moved to Business Development, leading Cancer Immunology licensing, and assumed his current role as head of the US BD&L team in early 2020. 

Product: Cedars-Sinai Accelerator

Company: Cedars-Sinai

About the Product:

The Cedars-Sinai Accelerator is transforming healthcare quality, efficiency, and care delivery by helping entrepreneurs bring their innovative technology products to market. This three-month program, based in Los Angeles, California, provides companies with $100,000 in funding, mentorship from leading clinicians and executives, access to Cedars-Sinai, and exposure to a broad network of entrepreneurs and investors.

Product: Women's and Children's Health Technology Fund

Company: Cross-Border Impact Ventures

About the Product:

Cross-Border Impact Ventures is an impact venture capital firm on a mission to revolutionize venture investing in health technology. Through the Women's and Children's Health Technology Fund, Cross-Border Impact Ventures invests in early-growth stage health technology companies commercializing medical devices, diagnostics, therapeutics, and digital health innovations and leveraging cutting-edge technologies like Artificial Intelligence (AI) and Machine Learning (ML). All innovations the Fund finances are relevant to women’s, children’s, and adolescents’ health and located in North America and Europe, with the ability to scale technologies to emerging markets. Cross-Border Impact Ventures is driven by the belief that good health should not be restricted by gender, age, race, wealth, or borders, and seeks to expand access to its portfolio’s world-class technologies inclusively and globally.

Product: Cube Labs

Company: Cube Labs

About the Product:

Cube Labs, Italy's leading venture builder in the healthcare technology space, bridges the gap between excellent local academic R&D and the global life sciences market. Evolving from its Italian origins, it has become a pan-European entity with a global reach. Cube Labs’ mission is to translate scientific research into impactful, real-world solutions while spearheading the democratization of life sciences for a healthier, more inclusive world where all individuals can benefit from innovation. Since its founding, Cube Labs has launched 15 startups and registered two products. In March 2023, it was listed on the Milan Stock Exchange, validating its vision and attracting growing interest in healthcare tech innovation.

Product: Venture Centre of Excellence (VCoE)

Company: EIT Health

About the Product:

The EIT Health Accelerator offers tip-to-tail pan-European support for innovative start-ups and SMEs across all life science and health subsectors to ensure that unmet patient and market needs are addressed at a truly global scale. Leveraging its 8+ year track record of supporting 2500+ start-ups, EIT Health Accelerator empowers fully tailored access to innovation for Corporates, VCs, payors and others, enabling collaboration with the best pan-European innovation. In so doing, the EIT Health Accelerator tackles critical global needs around healthcare innovation equity, both meeting present unmet needs and equipping the sector to resiliently face both known and unknown future challenges.

Product: McGill Dobson Centre for Entrepreneurship

Company: McGill Dobson Centre for Entrepreneurship

About the Product:

The McGill Dobson Centre for Entrepreneurship hub of entrepreneurship at McGill University with the mission to teach, coach, and support entrepreneurs stemming from McGill’s 11 faculties, 13 schools, and 35 research centers as they seek to build innovative companies with a purpose. With 14 learning pathways spanning four stages of the entrepreneurial journey and customized to different sectors, the Dobson Centre proudly stands as a global leader in entrepreneurship, committed to catalyzing sustainable socio-economic impact both locally and globally while addressing all 17 UN Sustainable Development Goals. With thousands of ventures supported, we count over 470 active startups who cumulatively raised $3.7 billion, own 109 active patents, created 10,000 jobs, operate in 38 countries, and collaborate with 88 universities.

Product: OROT - CONNECTED HEALTH INCUBATOR

Company: CIUSS WEST CENTRAL MONTREAL

About the Product:

OROT (Hebrew for ‘illumination’), a connected health innovation hub and incubator is one of the most comprehensive and distinctive innovation programmes in a healthcare setting in Canada, OROT has a mandate to support organisation-wide efforts to reimagine the future of care through adaptive culture change, strategic foresight, digital transformation and the co-creation of technology. Through its internationally recognised incubation programme, OROT also fosters the creation and commercialisation of the next generation of digital health technologies. OROT offers a unique and integrated environment based on interdisciplinary collaboration and the process of co-creation and validation of new technologies. The aim is to catalyse their development, commercialisation, market launch, and, ultimately, user adoption. Using this dynamic approach, OROT has made many unique endeavours possible.

Product: TechConnect

Company: TechConnect Venture Studio

About the Product:

TechConnect Venture Studio is an AI-driven platform focused on advancing precision health and climate resilience for global social impact. We leverage AI tools to accelerate drug development, particularly in rare diseases, traditionally underfunded and dispersed globally. Our work extends to a multi-model mental health companion designed to increase access to mental health services for underserved populations. Additionally, TechConnect explores the intersection of climate and health, addressing how environmental changes impact public health. Through innovative solutions and investing in emerging economies, we aim to bridge critical gaps in healthcare and drive global social impact.

Product: TMC Innovation

Company: Texas Medical Center Innovation

About the Product:

TMC Innovation is a pillar within the Texas Medical Center, dedicated to advancing life science innovation and improving patient outcomes. As part of the world’s largest medical city, with over 10 million patient encounters annually, TMC Innovation supports healthcare entrepreneurs from concept to commercialization. Its programs include the Accelerator for HealthTech, which nurtures early-stage startups, the TMC Biodesign fellowship for medical device innovation, and the Accelerator for Cancer Therapeutics, focused on breakthrough cancer treatments. Through these programs, TMC Innovation fosters collaboration across disciplines, driving both commercialization and clinical impact to shape the future of healthcare.